Do you reckon that this guy could spot a potential breakthrough drug if he saw it!
Reading from his executive profile, John Douglas Wilson was the former Senior VP for Medicine and Regulatory Affairs for Boehringer Ingelheim overseeing all clinical research programmes and interactions with the FDA. I wonder whether we can see Wilson's handprint in the formulation of an "externally facilitated process with appropriate experts" as Phylogica look to take a lead candidate forward for evaluation in a clinical trial.
Ann: Chairman Appointment, page-3
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.8¢ | 10.3¢ | $421.2K | 4.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 872943 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341133 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |